Abstract
Special patient groups, such as children and pregnant women, are not regularly included in drug development programs. Changes in physiological processes in these patients affect the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. This may result in suboptimal efficacy or substantial toxicity caused by under- or overexposure to these drugs.
... read more